<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02182440</url>
  </required_header>
  <id_info>
    <org_study_id>AP-recAP-AKI-02-01</org_study_id>
    <secondary_id>2014-000761-40</secondary_id>
    <nct_id>NCT02182440</nct_id>
  </id_info>
  <brief_title>A Safety, Tolerability, Efficacy and QoL Study of Human recAP in the Treatment of Patients With SA-AKI</brief_title>
  <acronym>STOP-AKI</acronym>
  <official_title>A DB Four-Arm, Parallel Group, Proof of Concept, Dose-Finding Adaptive Phase 2a/2b RCT to Investigate the Safety, Tolerability and Efficacy and Effect on QoL of Human Recombinant Alkaline Phosphatase in Patients With Sepsis-Associated AKI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AM-Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PPD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AM-Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether recombinant Alkaline Phosphatase (recAP) is
      effective and save, and to determine the most effective dose, in the treatment of patients
      with acute kidney injury caused by sepsis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design:

      Adaptive trial with two stages and interim analysis

        -  Stage 1: four arms; three dose groups and placebo. n=30/arm. (n=120)

        -  Interim analysis based on 120 subjects, with continued recruitment, adding 11 subjects
           to Stage 1 safety population (n=131): to evaluate safety and select dose for stage 2

        -  Stage 2: one dose group and placebo. N=85/arm. (n=170) Total n in the study: 301.

      Primary objectives

        -  To investigate the effect of recAP on renal function (measured creatinine clearance
           D1-D7 period, incidence and duration of renal replacement therapy (RRT) over 28 days,
           eGFR at D60 and D90) and related clinical parameters (ICU stay, Hospital stay,
           Mechanical ventilation over 28 days, SOFA and SAPS2 scores 28 days) in patients with
           SA-AKI.

        -  To determine effective therapeutic dose(s) of recAP.

      Secondary objectives

        -  To investigate the safety and tolerability of recAP in patients with SA AKI. (assessed
           by independent Data Monitoring Board, adverse events over 90 days study period,
           laboratory values, ECG, physical examniations, vital signs, Anti Drug Antibodies)

        -  To investigate the pharmacokinetic profile (PK) of recAP in a subset of patients (part
           1, n=120) with SA AKI. (Population PK; AUC D1-7, Cmax, Cmin, Tmax, terminal T1/2)

        -  To investigate the immunogenic potential of recAP in patients with SA AKI. (anti-drug
           antibodies at D14, D28, D60 and D90)

        -  To investigate the effect on quality of life (using the EuroQol, EQ-5D) following study
           inclusion, at ICU discharge, and Day 90.

      Other objectives

      • To evaluate whether specific patient groups can be identified that benefit most from recAP
      treatment or patient groups that are non-responders
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 18, 2014</start_date>
  <completion_date type="Actual">September 27, 2017</completion_date>
  <primary_completion_date type="Actual">May 25, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measured creatinine clearance (based on urine volume and creatinine concentrations)</measure>
    <time_frame>7 days</time_frame>
    <description>Urine collected daily for 4-8 hour periods. Creatinine clearance (ml/min) is calculated from urine volume, plasma and urinary creatinine concentrations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of renal replacement therapy (RRT)</measure>
    <time_frame>28 days</time_frame>
    <description>Start and stop of RRT is per criteria as defined in the protocol</description>
  </secondary_outcome>
  <other_outcome>
    <measure>To investigate the immunogenic potential of recAP</measure>
    <time_frame>D14, D28, D60, D90</time_frame>
    <description>Central laboratory anti-drug antibodies at visits on Days 14, 28, 60, and 90. Samples taken on Days 60 and 90 will only be analyzed in case of a positive result on Day 14</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Life</measure>
    <time_frame>pre study, ICU discharge, D90</time_frame>
    <description>EQ-5D</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">301</enrollment>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 hour IV infusion once daily for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.4 mg/kg (250 U/kg) recAP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 hour IV infusion once daily for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.8 mg/kg (500 U/kg) recAP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 hour IV infusion once daily for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.6 mg/kg (1000 U/kg) recAP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 hour IV infusion once daily for 3 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recAP</intervention_name>
    <description>One hour infusions once daily for three days</description>
    <arm_group_label>0.4 mg/kg (250 U/kg) recAP</arm_group_label>
    <arm_group_label>0.8 mg/kg (500 U/kg) recAP</arm_group_label>
    <arm_group_label>1.6 mg/kg (1000 U/kg) recAP</arm_group_label>
    <other_name>Recombinant Alkaline Phosphatase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 hour IV infusion once daily for 3 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed Informed Consent Form (patient, legal representative or independent
             investigator)

          2. Age 18 to 85 years, inclusive

          3. Is admitted to the ICU or Intermediate Care Unit

          4. Has diagnosis of sepsis (&lt; 96 hrs prior to first study drug), according to criteria
             defined by the American College of Chest Physicians/Society of Critical Care Medicine:

               1. Has a proven or strongly suspected bacterial infection.

               2. Has at least 2 of 4 SIRS criteria 72 hrs &lt; screening and 96 hrs &lt; first study
                  drug

          5. First diagnosis of AKI: AKI Stage 1 or greater, according to the AKIN criteria
             (time-window adjusted):

               1. Increase in serum creatinine &gt; 26.2 µmol/L (0.30 mg/dL) in 48 hrs prior to
                  screening, or

               2. Increase in serum creatinine to &gt; 150% (&gt; 1.5-fold) from reference creatinine
                  value in 48 hrs prior to screening

               3. Urinary output &lt; 0.5 mL/kg/h for &gt; 6 hours following adequate fluid resuscitation

          6. Continuing AKI needs to be confirmed by a confirmative fluid corrected serum
             creatinine measure, or

          7. When the AKI diagnosis was made according to the AKIN urine output criteria (urinary
             output &lt; 0.5 mL/kg/h for &gt; 6 hours), the oliguria or anuria should still meet the AKIN
             urine output criteria prior to randomization.

        Exclusion Criteria:

          1. Woman of childbearing potential with a positive pregnancy test, pregnant, or
             breastfeeding.

          2. Weighs more than 115 kg (253 lb).

          3. Has life support limitations.

          4. Is known to be human immunodeficiency virus positive.

          5. Has urosepsis.

          6. Is already on dialysis (RRT) or anticipated to receive RRT within 24 hours after study
             drug dosing due to the underlying disease.

          7. Is receiving immunosuppressant treatment or is on chronic high doses of steroids
             equivalent to prednisone/prednisolone 0.5 mg/kg/day, including solid organ transplant
             patients. Patients with septic shock treated with hydrocortisone (e.g., 3 × 100 mg)
             can be included.

          8. Is expected to have rapidly fatal outcome (within 24 hours).

          9. Has known, confirmed fungal sepsis.

         10. Has advanced chronic liver disease, confirmed by a Child-Pugh score of 10 to 15.

         11. Has acute pancreatitis with no established source of infection.

         12. Has participated in another investigational study within 30 days prior to enrollment.

         13. Is not expected to survive for 28 days due to medical conditions other than SA AKI,
             including cancer, end-stage cardiac disease, cardiac arrest requiring cardiopulmonary
             resuscitation or with pulseless electrical activity or asystole within the past 30
             days, end stage lung disease, and end stage liver disease.

         14. Has known prior history of Chronic Kidney Disease with a documented estimated
             Glomerular Filtration Rate (eGFR) &lt; 60 mL/min by Modification of Diet in Renal Disease
             MDRD or CKD-EPI formula, known GFR &lt; 60 mL/min, or a known history of persistent
             creatinine level &gt; 150 µmol/L (1.70 mg/dL) for reasons other than the current sepsis
             condition.

         15. Has diagnosis of malaria or other parasite infections.

         16. Has burns on &gt; 20% of body surface.

         17. Has had AKI diagnosis according to inclusion criteria &gt; 24 hours prior to study drug
             administration.

         18. Is anticipated to be treated with non-continuous RRT from Day 1 to Day 7.

         19. During Day 1 to Day 7 continuous RRT is anticipated to be started or stopped not
             according to per protocol criteria.

         20. The AKI is most likely attributable to other causes than sepsis, such as nephrotoxic
             drugs and renal perfusion-related.

         21. Improvement in serum creatinine of at least 0.30 mg/dL or (26.2 µmol/L) prior to
             administration of the study drug.

         22. Patients who use nephrotoxic medication and who fulfill the SA-AKI inclusion criteria
             at screening are not eligible if the use of this nephrotoxic medication is to continue
             when alternative, medically appropriate, non-nephrotoxic medication is available.

         23. Has a history of known IV drug abuse.

         24. Is an employee or family member of the investigator or study site personnel.

         25. Has active hematological malignancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacques Arend, MD DiMD</last_name>
    <role>Study Director</role>
    <affiliation>AM Pharma BV</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Pickkers, Prof MD. PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department Intensive Care, Radboud University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Idaho Medical Consultants LLC</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15261</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Houston Medical School</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <state>Tirol</state>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Allgemeine und Chirurgische Intensivmedizin</name>
      <address>
        <city>Innsbruck</city>
        <state>Tirol</state>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Erasme</name>
      <address>
        <city>Brussels</city>
        <state>Brussel</state>
        <zip>B-1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU UCL Mont Godinne</name>
      <address>
        <city>Yvoir</city>
        <state>Namur</state>
        <zip>B-5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Ghent</name>
      <address>
        <city>Gent</city>
        <state>Oost Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Antwerpen</name>
      <address>
        <city>Antwerpen</city>
        <zip>B-2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint Luc-UCL</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Brugmann</name>
      <address>
        <city>Brussels</city>
        <zip>B-1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussels</city>
        <zip>B-1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice u sv. Anny v Brne</name>
      <address>
        <city>Brno</city>
        <state>Jihomoravský Kraj</state>
        <zip>656 91</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oblastni nemocnice Kolin, a.s.</name>
      <address>
        <city>Kolin</city>
        <zip>280 02</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Plzen</name>
      <address>
        <city>Pilsen</city>
        <zip>30460</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsingin Yliopistollinen Keskussairaala</name>
      <address>
        <city>Helsinki</city>
        <zip>FI-00290</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kuopion Yliopistollinen Sairaala</name>
      <address>
        <city>Kuopio</city>
        <zip>70210</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampereen yliopistollinen sairaala</name>
      <address>
        <city>Tampere</city>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Universitaire Dupuytren</name>
      <address>
        <city>Limoges</city>
        <state>Haute-Vienne</state>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <state>Seine-Maritime</state>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Departemental de Vendee</name>
      <address>
        <city>La Roche sur Yon</city>
        <state>Vendée</state>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Lariboisière</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67090</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cork University Hospital</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's University Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Leeuwarden</name>
      <address>
        <city>Leeuwarden</city>
        <state>Friesland</state>
        <zip>8934 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboud University Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Canisius Wilhelmina Ziekenhuis</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6532 SZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Ziekenhuis</name>
      <address>
        <city>'s Hertogenbosch</city>
        <state>Noord-Brabant</state>
        <zip>5223 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VU Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <state>Overijssel</state>
        <zip>7513 ER</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medisch Centrum</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ikazia Ziekenhuis</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <zip>3083 AN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de La Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluna</state>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corporacio Sanitaria Parc Tauli</name>
      <address>
        <city>Sabadell</city>
        <state>Cataluna</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Mutua de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Cataluña</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <state>Madrid, Communidad Delaware</state>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de A Coruña</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>﻿08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Tarragona Joan XXIII</name>
      <address>
        <city>Tarragona</city>
        <zip>43007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Infirmary of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4SB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal London Hospital</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St James University Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Ireland</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Italy</country>
  </removed_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2014</study_first_submitted>
  <study_first_submitted_qc>July 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2014</study_first_posted>
  <last_update_submitted>December 4, 2017</last_update_submitted>
  <last_update_submitted_qc>December 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SA-AKI</keyword>
  <keyword>Sepsis</keyword>
  <keyword>AKI</keyword>
  <keyword>Recombinant Alkaline Phosphatase</keyword>
  <keyword>recAP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

